US agency updates rules on sharing genomic data
By Richard Van Noorden,
Nature News
| 09. 01. 2014
Scientists who work on genomics and are funded by the US National Institutes of Health (NIH) must post their data online so that others can build on the information, the agency has said in an update to its guidelines.
The change, which expands the remit of an earlier data-sharing policy, is not expected to drastically alter research practices — many genomics researchers are accustomed to sharing their data. But the latest policy, released on 27 August, gives clearer instructions for gaining the informed consent of study participants. The NIH will now require researchers to tell study participants that their data may be broadly shared for future research.
Informed consent will be required not just for genomic data, but also for cell lines or clinical specimens such as tissue samples, even when they are stripped of information that directly identify the source. That extension, which the NIH has not previously required, is a “big step”, says Ellen Wright Clayton, a bioethicist and lawyer at Vanderbilt University in Nashville, Tennessee.
The agency has been working on the changes for several years, as...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...